StockWatch
·
Biotechnology: Pharmaceutical Preparations
Quarterly ResultMay 7, 2026, 04:22 PM

Annexon Q1 Net Loss Narrows to $44.1M; R&D Expenses Down

AI Summary

Annexon, Inc. reported a net loss of $44.1 million for Q1 2026, a significant improvement from $54.4 million in Q1 2025, primarily driven by a decrease in research and development expenses. The company's cash and short-term investments stood at $225.0 million as of March 31, 2026, and management expects this to fund operations for at least twelve months. Financing activities included raising $32.7 million through its 2024 ATM program and establishing a new $150.0 million 2026 ATM program.

Key Highlights

  • Net loss decreased to $44.1 million in Q1 2026 from $54.4 million in Q1 2025.
  • Net loss per share improved to $(0.23) in Q1 2026 from $(0.37) in Q1 2025.
  • Research and development expenses decreased to $35.8 million from $48.2 million YoY.
  • Cash and short-term investments totaled $225.0 million as of March 31, 2026.
  • Raised $32.7 million net from 2024 ATM program in Q1 2026.
  • Established a new $150.0 million 2026 ATM program in March 2026.
  • Net cash used in operating activities was $46.8 million, down from $50.1 million YoY.